Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
25
2023
FDA Finalizes Cannabis Guidance Focusing on Clinical Research and Quality Considerations Nelson Mullins
Jan
29
2024
Gold Dome Report – Legislative Day 10 (2024) Nelson Mullins
Jul
12
2021
Biden Executive Order Addresses Healthcare Industry Competition, Targets Pharmaceuticals, Pricing, and Hospital Mergers Nelson Mullins
Apr
6
2023
FDA Announces First-Ever AI/ML Medical Device Draft Guidance Nelson Mullins
Jun
30
2023
Old North State Report – June 30, 2023 Nelson Mullins
Apr
17
2023
FDA Publishes Implementation Policy Regarding Cybersecurity Requirements for Medical Device Premarket Submissions Nelson Mullins
Jun
12
2023
New FDA Draft Guidance Updates Recommendations for Good Clinical Practices Nelson Mullins
Jul
10
2023
Payment Cuts and Program Changes: CMS Issues Calendar Year 2024 Home Health Prospective Payment System Proposed Rule Nelson Mullins
Aug
31
2023
Two New Drug Supply Chain Security Act Guidance to Help Pharmaceutical Supply Chain Partners Comply with the DSCSA’s Move to Electronic Tracking Nelson Mullins
Oct
24
2023
FDA Updates Guidance Regarding Scientific Communications to HCPs about Unapproved Uses of Approved/Cleared Medical Devices and Drugs Nelson Mullins
Jan
22
2024
Gold Dome Report – Legislative Day 6 (2024) Nelson Mullins
Mar
1
2024
Gold Dome Report - Crossover Day Wrap-Up Nelson Mullins
Sep
21
2021
Changing Course, CMS Proposes to Repeal Medicare Coverage Pathway for FDA-Designated “Breakthrough Devices” Nelson Mullins
Oct
11
2021
HHS Rescinds Rule to Provide Insulin and Injectable Epinephrine at 340B Prices Nelson Mullins
Sep
14
2023
Stark Integrity Podcast: FCA, CARES Act, and Call Arrangements Episodes [Podcast] Nelson Mullins
Aug
15
2023
FDA Finalizes Informed Consent Guidance for Drug and Medical Device Clinical Investigations Nelson Mullins
Oct
3
2022
FDA Concludes Software Pre-Cert Pilot Program, Noting Federal Legislative Action is Needed Nelson Mullins
Feb
20
2023
Old North State Report – Feb. 20, 2023 Nelson Mullins
Jun
9
2023
Old North State Report – June 5, 2023 Nelson Mullins
Jul
18
2023
Hospital Price Transparency Changes in the Calendar Year 2024 Hospital Outpatient Prospective Payment System Proposed Rule Nelson Mullins
Sep
22
2021
Ushering in a New Era of OTC Drug Regulation, FDA Posts First Batch of “Deemed” Final Administrative Orders Nelson Mullins
Oct
26
2021
FDA Convenes Medical Device Workshop Focused on Artificial Intelligence and Machine Learning Transparency Nelson Mullins
Oct
24
2019
Beef Buyer Class Action Says ‘Big Beef’ Colluded to Score Record Profits by Manipulating Capacity MoginRubin
Mar
24
2020
Enforcers, Experts Discuss Tamping Down Anticompetitive Behavior in Bio Market During FDA/FTC Workshop MoginRubin
Dec
18
2019
FTC Challenges Illumina-PacBio Merger over for Next-Gen DNA Sequencing MoginRubin
Mar
4
2022
Big Beer Says Prices have Remained Low While Craft Brewers Welcome the Scrutiny. MoginRubin
Sep
18
2019
‘Big Tuna’ Antitrust Case Among Latest to Discuss Daubert Test at Class Certification Stage. But What’s Too Rigorous? MoginRubin
Feb
28
2020
FTC, FDA Team Up Against Anticompetitive Tactics in Biological Product Industry MoginRubin
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins